Abbott Laboratories (ABT) stock
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3049% above fair value
$108.52+1.27 (+1.18%)
Close on Nov 13, 2026Market cap $187.78BP/E 40.2Yield 2.21%
Abbott Laboratories gross margin
Gross margin is gross profit as a percentage of revenue.
Abbott Laboratories's gross margin for the twelve months ending Sep 30, 2026 was 56.9%. For fiscal 2025 it was 56.4%, against 55.4% the year before. The highest annual figure on record is 58.5% in fiscal 2019.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 56.4% | +1.0 |
| FY2024 | Dec 31, 2024 | 55.4% | +0.2 |
| FY2023 | Dec 31, 2023 | 55.2% | −1.0 |
| FY2022 | Dec 31, 2022 | 56.1% | −0.8 |
| FY2021 | Dec 31, 2021 | 57.0% | +0.3 |
| FY2020 | Dec 31, 2020 | 56.6% | −1.9 |
| FY2019 | Dec 31, 2019 | 58.5% | +0.1 |
| FY2018 | Dec 31, 2018 | 58.4% | +3.8 |
| FY2017 | Dec 31, 2017 | 54.7% | −1.7 |
| FY2016 | Dec 31, 2016 | 56.4% | −0.7 |
| FY2015 | Dec 31, 2015 | 57.1% | +2.7 |
| FY2014 | Dec 31, 2014 | 54.5% | +1.2 |
| FY2013 | Dec 31, 2013 | 53.2% | −0.1 |
| FY2012 | Dec 31, 2012 | 53.3% | +0.1 |
| FY2011 | Dec 31, 2011 | 53.2% | −5.1 |
| FY2010 | Dec 31, 2010 | 58.3% | +1.2 |
| FY2009 | Dec 31, 2009 | 57.1% | −0.2 |
| FY2008 | Dec 31, 2008 | 57.3% | +1.4 |
| FY2007 | Dec 31, 2007 | 55.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 56.8% | +1.4 |
| Q2 FY2026 | Jun 30, 2026 | 57.7% | +1.3 |
| Q1 FY2026 | Mar 31, 2026 | 56.2% | −0.7 |
| Q4 FY2025 | Dec 31, 2025 | 57.0% | +2.1 |
| Q3 FY2025 | Sep 30, 2025 | 55.4% | −0.5 |
| Q2 FY2025 | Jun 30, 2025 | 56.4% | +0.8 |
| Q1 FY2025 | Mar 31, 2025 | 56.9% | +1.7 |
| Q4 FY2024 | Dec 31, 2024 | 55.0% | −0.5 |
| Q3 FY2024 | Sep 30, 2024 | 55.8% | +1.2 |
| Q2 FY2024 | Jun 30, 2024 | 55.6% | +0.6 |
| Q1 FY2024 | Mar 31, 2024 | 55.2% | −0.4 |
| Q4 FY2023 | Dec 31, 2023 | 55.5% | +1.0 |
| Q3 FY2023 | Sep 30, 2023 | 54.6% | −0.9 |
| Q2 FY2023 | Jun 30, 2023 | 55.1% | −1.1 |
| Q1 FY2023 | Mar 31, 2023 | 55.6% | −2.5 |
| Q4 FY2022 | Dec 31, 2022 | 54.5% | −4.0 |
| Q3 FY2022 | Sep 30, 2022 | 55.5% | −4.0 |
| Q2 FY2022 | Jun 30, 2022 | 56.2% | +4.6 |
| Q1 FY2022 | Mar 31, 2022 | 58.1% | +0.2 |
| Q4 FY2021 | Dec 31, 2021 | 58.4% | +0.4 |
| Q3 FY2021 | Sep 30, 2021 | 59.5% | +4.3 |
| Q2 FY2021 | Jun 30, 2021 | 51.6% | −3.9 |
| Q1 FY2021 | Mar 31, 2021 | 57.9% | +0.4 |
| Q4 FY2020 | Dec 31, 2020 | 58.0% | +5.1 |
| Q3 FY2020 | Sep 30, 2020 | 55.2% | +2.8 |
| Q2 FY2020 | Jun 30, 2020 | 55.5% | +2.6 |
| Q1 FY2020 | Mar 31, 2020 | 57.5% | +5.9 |
| Q4 FY2019 | Dec 31, 2019 | 52.9% | +0.3 |
| Q3 FY2019 | Sep 30, 2019 | 52.4% | +0.9 |
| Q2 FY2019 | Jun 30, 2019 | 52.9% | +2.3 |
| Q1 FY2019 | Mar 31, 2019 | 51.6% | +1.0 |
| Q4 FY2018 | Dec 31, 2018 | 52.6% | +3.2 |
| Q3 FY2018 | Sep 30, 2018 | 51.5% | +1.0 |
| Q2 FY2018 | Jun 30, 2018 | 50.5% | +4.5 |
| Q1 FY2018 | Mar 31, 2018 | 50.6% | +7.2 |
| Q4 FY2017 | Dec 31, 2017 | 49.4% | −5.0 |
| Q3 FY2017 | Sep 30, 2017 | 50.5% | – |
| Q2 FY2017 | Jun 30, 2017 | 46.0% | – |
| Q1 FY2017 | Mar 31, 2017 | 43.4% | – |
| Q4 FY2016 | Dec 31, 2016 | 54.4% | – |
See a number that looks wrong?